TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
Background: Teclistamab is the first approved off-the-shelf BCMA×CD3 bispecific antibody, with personalized weight based dosing, for the treatment of patients (pts) with RRMM based on data from the pivotal phase 1/2 MajesTEC-1 study (NCT03145181/NCT04557098). Moreau et al (NEJM 2022) reported rapid,...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2023-10-01
|
| Serie: | Hematology, Transfusion and Cell Therapy |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S253113792300929X |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|